Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations

Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations

Abstract Cancer cells with BRCA1/2 deficiencies are sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. We evaluated the efficacy of talazoparib in DNA-Damage Repair (DDR)-altered patients. In this phase II trial, patients were enrolled onto one of four cohorts based on molecular alteration...

Full description

Bibliographic Details
Main Authors: Sarina A. Piha-Paul, Chieh Tseng, Cheuk Hong Leung, Ying Yuan, Daniel D. Karp, Vivek Subbiah, David Hong, Siqing Fu, Aung Naing, Jordi Rodon, Milind Javle, Jaffer A. Ajani, Kanwal P. Raghav, Neeta Somaiah, Gordon B. Mills, Apostolia M. Tsimberidou, Xiaofeng Zheng, Ken Chen, Funda Meric-Bernstam
Format: Article
Language:English
Published: Nature Portfolio 2024-07-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-024-00634-6

Internet

https://doi.org/10.1038/s41698-024-00634-6

Similar Items